TipRanks on MSN

NovaBridge posts strong phase 1b givastomig data and prepares global phase 2 in first-line gastric cancer

NovaBridge Biosciences ( ($NBP) ) just unveiled an update. On January 6, 2026, NovaBridge Biosciences reported updated Phase 1b data showing that ...

NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer

Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and ...
Fierce Pharma

UPDATED: Jazz touts Ziihera as the new HER2 agent of choice in stomach cancer

Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...
Morningstar

Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab

HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in ...
pharmaphorum

Hengrui gets first OK for a PD-L1/TGF-beta drug for cancer

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall ...

Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and ...
Brattleboro Reformer

Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab

These low and negative PD-L1 patients constitute well more than half of the total gastric cancer patient population. In 2024, the FDA narrowed the indication for all approved PD-1 inhibitors in the ...